2403. Clorazepic Acid

Nomenclature

CAS number: 23887-31-2
7-Chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid.
C16H11ClN2O3; mol wt 314.72.
C 61.06%, H 3.52%, Cl 11.26%, N 8.90%, O 15.25%.

Description and references

Prepn: NL 6507637; J. Schmitt, US 3516988; reissued as US RE 28315 (1965, 1970, 1975 all to Clin-Byla). Synthesis and activity of the dipotassium salt: J. Schmitt et al., Chim. Ther. 4, 239 (1969). Solution chemistry: R. Raveux, M. Briot, ibid. 303. Metabolism: P. Gros, R. Raveux, ibid. 312. Toxicity data: M. Brunaud et al., Arzneim.-Forsch. 20, 123 (1970). Series of articles on pharmacology and clinical use: ibid, 123-137. HPLC determn in plasma: P. Colin, G. Sirois, J. Chromatogr. 273, 367 (1983). Clinical trial in anxiety: W. W. K. Zung, J. Clin. Psychiatry 48, 13 (1987); in comparison with buspirone, q.v.: K. Rickels et al., Arch. Gen. Psychiatry 45, 444 (1988). Comprehensive description: J. A. Raihle, V. E. Papendick, Anal. Profiles Drug Subs. 4, 91-112 (1975).

Chemical structure

Derivative

Dipotassium salt.

Nomenclature

CAS number: 57109-90-7
7-Chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid monopotassium salt compd with potassium hydroxide; clorazepate dipotassium; Abbott 35616; CB-4306; Belseren (BMS); Mendon (Dainippon); Tranxilène (Clin-Comar-Byla); Tranxilium (Mack, Illert.); Transene (Clin-Comar-Byla); Tranxene (Abbott).
C16H11ClK2N2O4; mol wt 408.92.
C 46.99%, H 2.71%, Cl 8.67%, K 19.12%, N 6.85%, O 15.65%.

Properties

White powder, freely sol in water. Very poorly sol in ethanol. Practically insol in ether, chloroform. Aq solns are alkaline to phenolphthalein. uv max (anhydrous product in water): 231, 311 nm (ε 33500, 2450). LD50 in mice (mg/kg): 700 orally; 290 i.p. LD50 orally in rats: >1000 mg/kg (Brunaud).

Derivative

Monopotassium salt.

Nomenclature

CAS number: 5991-71-9
CB-4311; Azene (Endo).
C16H10ClKN2O4; mol wt 368.81.
C 52.11%, H 2.73%, Cl 9.61%, K 10.60%, N 7.60%, O 17.35%.

Note

This is a controlled substance (depressant): 21 CFR, 1308.14.

Therapeutic Category

Anxiolytic.

Keywords

Anxiolytic; Benzodiazepine Derivatives